The European Medicines Agency (EMA) has identified a ‘very rare’ side effect associated with semaglutide treatment, known as nonarteritic anterior ischemic optic neuropathy (NAION). This information comes after an exhaustive review conducted by the Pharmacovigilance Risk Assessment Committee (PRAC). The committee combed through a variety of data sources, including nonclinical studies, clinical trials, postmarketing surveillance, and available medical literature.
Large epidemiological studies provided a critical insight – adults with type 2 diabetes who were on semaglutide had double the risk of developing NAION compared to nonusers. This was backed by clinical trials which demonstrated a slightly elevated risk of this eye condition with the use of the GLP-1 drug compared to a placebo.
NAION, which can lead to vision loss, is an eye condition caused by a decrease in blood flow to the optic nerve. This reduction in blood flow can result in nerve damage and potentially blindness. It’s estimated that up to one out of every 10,000 people taking semaglutide, sold under trade names Ozempic, Rybelsus, and Wegovy (Novo Nordisk) for the treatment of diabetes and obesity, may be affected by NAION.
In light of these findings, the EMA has recommended that semaglutide’s labeling be updated to reflect this new information about the potential risk of NAION. The agency has urged patients experiencing a sudden loss of vision or rapidly deteriorating eyesight during semaglutide treatment to contact their healthcare provider immediately. If NAION is confirmed, treatment with semaglutide should be discontinued.
Earlier this year, the EMA had indicated its intention to investigate the possible link between semaglutide treatment and NAION after certain studies hinted at an association, although not all studies concurred. The PRAC’s review of the available data has now substantiated this link, underscoring the need for caution and vigilance.
This safety update reinforces the importance of closely monitoring the potential side effects of semaglutide therapy, particularly for patients with type 2 diabetes. Healthcare providers should remain vigilant in recognizing symptoms of NAION and consider the risk-benefit profile when prescribing GLP-1 drugs like semaglutide. The findings from the EMA highlight the ongoing efforts to ensure the safety and efficacy of pharmaceutical interventions for diabetes management.
As we move forward, continued research and surveillance are necessary to better understand the mechanisms behind this rare side effect. Such efforts will contribute to optimizing the safe use of these medications in the diabetic population, ultimately improving disease management and patient outcomes. The insights gained from this research will not only guide clinical practice but also influence future drug development in the field of diabetes and obesity treatment.
Read more from tctmd.com
